BrainFutures Launches Initiative to Accelerate National Adoption of Psychedelic-Assisted Therapy
This spring, BrainFutures launched a tiered initiative to catalyze the national adoption of psychedelic medicines for the treatment of mental health disorders.
The promise and timing of these breakthrough treatments has reached an inflection point. Clinical research being conducted internationally and in approved U.S. university labs has shown some striking results related to psychedelic-assisted therapy for a range of intractable conditions, including end-of-life anxiety, PTSD, treatment-resistant depression, major depressive disorder, alcohol and nicotine dependency, and drug addiction. These results have earned several companies running clinical trials "Breakthrough Therapy" status from the FDA.
Holly McCormack, Chief Strategy Officer of BrainFutures, shares, "With our extraordinary team of health care reform veterans and expert advisors, we are well positioned to anticipate the structural obstacles this fast-moving field will face as it merges with the incumbent behavioral health system. We aim to bring our expertise and networks together to help minimize the pitfalls brought about by this confluence, particularly as it relates to regulatory and reimbursement considerations."
